Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty - Kereiakes, D J; Kleiman, N S; Ambrose, J; Cohen, M; Rodriguez, S; Palabri, T; Herrmann, H C; Sutton, J M; Weaver, W D; McKee, D B; Fitzpatrick, V; Sax, F L (J Am Coll Cardiol, 1996)